TL;DR: Lion’s mane mushroom contains compounds (hericenones and erinacines) that stimulate nerve growth factor synthesis in cell and animal studies, and a handful of small human trials suggest cognitive benefits in older adults with mild impairment. However, the clinical evidence is still limited – small sample sizes, few independent replications, and no large-scale RCTs. Supplement quality is a serious concern: many products are mycelium grown on grain with minimal active compounds. If you choose to try lion’s mane, select a dual-extract product standardized for beta-glucans and hericenones, use 500–3,000 mg/day, and maintain realistic expectations. It is not yet in the same evidence tier as omega-3, creatine, or citicoline.
Introduction
Few supplements have ridden the wellness wave quite like lion’s mane mushroom. Scroll through any nootropic forum or health-oriented social media feed and you will encounter bold claims: lion’s mane regrows neurons, reverses brain fog, prevents dementia, and functions as nature’s own smart drug. The marketing language is dramatic. The underlying science is more measured – but also more interesting than most people realize.
Lion’s mane (Hericium erinaceus) is a large, white, shaggy mushroom that grows on hardwood trees throughout North America, Europe, and Asia. It has been used in traditional Chinese and Japanese medicine for centuries, primarily for digestive health and general vitality. Its modern reputation as a brain supplement rests on a specific and genuinely fascinating mechanism: the stimulation of nerve growth factor, a protein essential for neuronal survival, growth, and repair.
The question is whether this mechanism – well-demonstrated in petri dishes and rodent brains – translates to meaningful cognitive benefits in living, thinking human beings. The honest answer is: probably, but we do not yet have the evidence to say so with confidence. This article breaks down what we know, what we do not, and how to navigate the supplement market if you decide to give lion’s mane a try.
What Is Lion’s Mane?
The Mushroom
Hericium erinaceus belongs to the tooth fungus group and is readily identifiable by its cascading white spines, which give it a striking resemblance to a lion’s mane – hence the common name. In Japan it is known as yamabushitake (mountain priest mushroom), and in China as hou tou gu (monkey head mushroom). It is both a culinary and medicinal mushroom: when cooked fresh, it has a mild, slightly sweet flavor often compared to lobster or crab.
Unlike many medicinal mushrooms that are too tough or bitter to eat (such as reishi or chaga), lion’s mane is a genuinely enjoyable food. However, most people interested in its cognitive effects turn to concentrated supplements, since the quantities of active compounds in a typical culinary serving are modest.
Active Compounds: Hericenones and Erinacines
The bioactive compounds responsible for lion’s mane’s neurological effects fall into two major classes:
Hericenones (A through H) are found primarily in the fruiting body – the visible mushroom itself. These are aromatic compounds that have been shown in cell culture studies to stimulate the synthesis of nerve growth factor (NGF). The key early research was conducted by Kawagishi and colleagues in the 1990s, who isolated and characterized these compounds and demonstrated their NGF-inducing activity in cultured astrocytes (Kawagishi et al., 1991, Tetrahedron Letters; Kawagishi et al., 1994, Bioscience, Biotechnology, and Biochemistry).
Erinacines (A through I) are found primarily in the mycelium – the root-like network of the fungus that grows through its substrate. Erinacines are diterpenoids, structurally distinct from hericenones, but they also stimulate NGF synthesis. Erinacine A, in particular, has shown potent NGF-stimulating activity in both cell culture and animal studies (Kawagishi et al., 1996, Tetrahedron Letters). Importantly, erinacines are small enough to cross the blood-brain barrier, which is a critical advantage for any compound intended to affect the central nervous system.
Both classes of compounds are considered necessary for the full spectrum of lion’s mane’s neurological effects. This has direct implications for supplement selection, as we will discuss later.
The NGF Mechanism: Why It Matters
What Is Nerve Growth Factor?
Nerve growth factor is a neurotrophin – a type of signaling protein that supports the survival, development, and function of neurons. Discovered by Rita Levi-Montalcini and Stanley Cohen (who shared the 1986 Nobel Prize in Physiology or Medicine for the discovery), NGF is particularly important for cholinergic neurons in the basal forebrain, the population of cells most severely affected in Alzheimer’s disease.
NGF does several things that matter for cognitive health:
- It promotes the survival of existing neurons, preventing programmed cell death (apoptosis).
- It stimulates neurite outgrowth – the extension of axons and dendrites that form the physical connections between neurons.
- It supports myelination, the process by which nerve fibers are insulated with a fatty sheath that speeds signal transmission.
- It enhances synaptic plasticity, the ability of synapses to strengthen or weaken in response to activity, which underlies learning and memory.
NGF levels decline with age, and this decline is correlated with the cognitive deterioration seen in both normal aging and neurodegenerative diseases. The therapeutic logic of lion’s mane is straightforward: if you can boost NGF production, you may be able to slow, halt, or even partially reverse neuronal deterioration.
From Cell Culture to Animal Models
The NGF-stimulating activity of hericenones and erinacines is well-established in vitro. When astrocyte cells (a type of brain support cell that naturally produces NGF) are exposed to these compounds, they significantly increase NGF secretion. This is not a subtle effect – in some studies, NGF output doubled or tripled compared to controls.
Animal studies have extended these findings. Mori et al. (2008) showed that mice fed lion’s mane mycelium enriched in erinacines demonstrated increased NGF levels in the hippocampus and enhanced performance on memory tasks. Brandalise et al. (2017) found that lion’s mane supplementation promoted hippocampal neurogenesis – the birth of new neurons – in wild-type mice, alongside improvements in recognition memory. Kolotushkina et al. (2003) demonstrated that lion’s mane extracts promoted neurite outgrowth and accelerated the myelination of nerve processes in cultured neurons.
These are genuinely compelling results. The problem, as with many promising preclinical findings, is the gap between showing an effect in cells and rodents and confirming it in the vastly more complex human brain.
Human Clinical Evidence
The Mori et al. 2009 Trial
The most frequently cited human study is the double-blind, placebo-controlled trial conducted by Mori and colleagues (2009), published in Phytotherapy Research. This study randomized 30 Japanese men and women aged 50 to 80, all diagnosed with mild cognitive impairment (MCI), to receive either lion’s mane extract or placebo for 16 weeks.
The treatment group received four 250 mg tablets three times daily (3 g/day total) of a dried lion’s mane powder. Cognitive function was assessed using the Revised Hasegawa Dementia Scale (HDS-R), a widely used screening tool in Japanese clinical practice comparable in sensitivity to the Mini-Mental State Examination (MMSE).
The results were positive: the lion’s mane group showed significantly greater improvement in cognitive scores at weeks 8, 12, and 16 compared to placebo. The improvements were progressive – scores continued to increase over the 16-week treatment period.
However, there was a notable finding in the follow-up: four weeks after supplementation ceased, cognitive scores in the lion’s mane group declined back toward baseline. This suggests that the benefits require continued use and do not reflect permanent neurological changes – at least not over a 16-week period.
While these results are encouraging, several limitations must be acknowledged. The sample size was small (30 participants). The study was conducted entirely in a Japanese population, limiting generalizability. The HDS-R, while validated, is a screening instrument rather than a comprehensive neuropsychological battery. And no independent research group has fully replicated this specific trial.
Saitsu et al. 2019
Saitsu and colleagues (2019) conducted a randomized, double-blind, placebo-controlled trial examining lion’s mane supplementation in 31 healthy Japanese adults aged 50 and older. Participants received either lion’s mane tablets (containing 0.5 g of fruiting body extract per tablet, three tablets daily) or placebo for 12 weeks.
The study assessed cognitive function using a battery of tests and found that lion’s mane supplementation significantly improved scores on certain cognitive domains compared to placebo. The researchers observed improvements that they attributed to the prevention of short-term memory decline. As with the Mori trial, sample size was modest and the study was conducted in a single ethnic population.
Li et al. 2020
Li and colleagues (2020) published a study in Frontiers in Aging Neuroscience investigating the effects of Hericium erinaceus mycelia enriched in erinacine A on mild Alzheimer’s disease. In this 49-week, randomized, double-blind, placebo-controlled trial involving 49 participants, the treatment group received 350 mg capsules of erinacine A-enriched mycelium three times daily.
The results showed that participants receiving the lion’s mane preparation had significantly higher cognitive scores (measured by MMSE, IADL, and CASI scales) compared to placebo, with particular benefits observed in those with milder disease. Neuroimaging biomarkers also showed trends toward benefit. While this trial extended the evidence into a clinical Alzheimer’s population and used a longer treatment duration, the sample size was again small, and the specific erinacine A-enriched preparation used is not widely available in consumer products.
What the Human Evidence Actually Shows
Taking the clinical trials together, here is a fair summary:
- Multiple small RCTs have shown that lion’s mane supplementation produces statistically significant improvements in cognitive test scores in older adults with mild cognitive impairment or early-stage dementia.
- The effect sizes are modest but clinically noticeable.
- Benefits appear to require ongoing supplementation – they do not persist after discontinuation (at least over the timeframes studied).
- All major trials have been conducted in Japanese or East Asian populations with relatively small sample sizes (30-50 participants).
- No large-scale, multi-site trial comparable to the major omega-3 or ginkgo studies has been conducted.
The evidence is preliminary to moderate. It is far ahead of most nootropic supplements that rely entirely on preclinical data and user testimonials, but it falls short of the standard needed for confident clinical recommendations.
Animal Evidence: Neurogenesis and Myelination
Beyond the human trials, a substantial body of animal research provides biological plausibility for lion’s mane’s cognitive effects:
Neurogenesis. Brandalise et al. (2017) demonstrated that oral lion’s mane supplementation increased the number of newly born neurons in the hippocampus of adult mice, a process called adult hippocampal neurogenesis. The hippocampus is the brain region most critical for forming new memories, and the rate of neurogenesis in this area declines with age. This finding aligns with the NGF-stimulation mechanism, since NGF promotes the differentiation and survival of neural precursor cells.
Myelination. Several studies have shown that lion’s mane extracts promote the myelination of nerve fibers in both cell culture and animal models. Myelin is the insulating sheath that speeds electrical signal transmission along axons. Demyelination is a hallmark of conditions like multiple sclerosis, but even normal aging involves gradual myelin deterioration, contributing to slower processing speed. If lion’s mane can support myelin maintenance, this could have broad relevance for cognitive aging.
Neuroprotection. Rodent studies have demonstrated protective effects against amyloid-beta-induced neurotoxicity (a model relevant to Alzheimer’s disease), reduced markers of oxidative stress in the brain, and attenuation of anxiety and depression-like behaviors. Zhang et al. (2016) showed that erinacine A reduced amyloid plaque burden and improved cognitive performance in transgenic Alzheimer’s model mice.
The animal evidence is encouraging. But it is worth remembering that the history of neuroscience is littered with compounds that showed remarkable promise in rodents and failed in human trials. The translation gap is real, and it demands that we hold lion’s mane to the same evidentiary standard as any other intervention.
Supplement Quality: A Critical Issue
Perhaps nowhere in the supplement industry is the gap between label claims and product reality as wide as it is in the mushroom supplement market. Understanding the basics of mushroom cultivation and extraction is essential for choosing a product that contains what it claims.
Fruiting Body vs. Mycelium on Grain
This is the single most important distinction in mushroom supplement quality.
Fruiting body products are made from the actual mushroom – the visible, above-ground structure. Fruiting body supplements contain higher concentrations of hericenones, beta-glucans (the primary bioactive polysaccharides), and other secondary metabolites. Well-made fruiting body extracts typically contain 25-50 percent beta-glucans by weight.
Mycelium-on-grain products are made by growing lion’s mane mycelium on a substrate of sterilized grain (usually rice or oats). Here is the problem: at harvest, the mycelium cannot be fully separated from the grain substrate. As a result, a significant proportion of the final product – sometimes the majority – is grain starch rather than actual fungal material. Independent testing has shown that some mycelium-on-grain products contain as little as 5 percent beta-glucans, with the remainder being primarily starch.
This matters because the grain starch contributes nothing to the purported neurological benefits. A consumer taking a mycelium-on-grain product may be getting a fraction of the active compounds they expect, despite the label displaying impressive milligram counts.
The exception to this rule involves erinacines. Since erinacines are found primarily in the mycelium rather than the fruiting body, a mycelium-based product is not inherently inferior – provided the mycelium is grown on liquid culture (submerged fermentation) rather than on grain, and the erinacine content is verified by third-party testing. The Li et al. (2020) trial used an erinacine A-enriched mycelium preparation produced under controlled conditions – a very different product from a mass-market mycelium-on-grain supplement.
Extraction Methods
Lion’s mane supplements are available as simple dried powders or as concentrated extracts. Extraction matters because many of the bioactive compounds are locked within the fungal cell walls, which are made of chitin – a tough polymer that human digestive enzymes cannot break down effectively.
Hot water extraction breaks down chitin and releases beta-glucans and hericenones into a soluble form. This is the traditional method used in medicinal mushroom preparations and is supported by the most clinical research.
Alcohol (ethanol) extraction captures additional non-water-soluble compounds, including certain terpenes and sterols.
Dual extraction (hot water followed by alcohol) captures the broadest range of bioactive compounds and is generally considered the gold standard for medicinal mushroom supplements.
A raw, unextracted mushroom powder is the least effective delivery method, since the chitin cell walls limit bioavailability. Many inexpensive lion’s mane products are simply dried, ground mushroom or mycelium-on-grain powder with no extraction step.
What to Look For on the Label
When evaluating a lion’s mane supplement, check for the following:
- Beta-glucan content specified as a percentage (aim for at least 25 percent). This is the most reliable indicator of a quality mushroom product.
- Starch content disclosed or independently tested. A high starch percentage indicates a grain-heavy mycelium product.
- Extraction method stated (hot water, alcohol, or dual extract).
- Source material identified (fruiting body, mycelium, or both).
- Third-party testing by an independent lab for purity, potency, and contaminant screening.
Products that list only total milligrams without disclosing beta-glucan content, extraction method, or source material should be treated with skepticism.
Dosing and Safety
Dosing
Based on the available clinical trials and traditional use, the commonly studied and recommended dosage range for lion’s mane is 500–3,000 mg per day of a concentrated extract. The Mori et al. (2009) trial used 3,000 mg/day of dried powder (not a concentrated extract), so this represents the upper end of the range for non-extracted preparations. For a standardized dual extract with verified beta-glucan content, 1,000–2,000 mg/day is a reasonable starting point.
There is no established optimal timing for lion’s mane supplementation. Some users report that taking it in the morning supports focus throughout the day, but no clinical study has specifically investigated timing effects. Splitting the dose between morning and midday is a common approach.
Unlike some nootropics, lion’s mane does not appear to produce acute, noticeable effects. The clinical trials that showed benefits used supplementation periods of 8–16 weeks or longer. Expect a gradual onset, if any, and allow at least two to three months before evaluating efficacy.
Safety Profile
Lion’s mane has a favorable safety profile based on the available evidence. It has been consumed as a food in East Asia for centuries, and no serious adverse effects have been reported in clinical trials at doses up to 3 g/day over 16 weeks.
Known considerations include:
Gastrointestinal discomfort. Some users report mild stomach upset, particularly at higher doses or on an empty stomach. This is typically resolved by taking lion’s mane with food or reducing the dose.
Allergic reactions. Rare cases of allergic contact dermatitis and respiratory allergies have been reported, primarily in individuals with known mushroom sensitivities. Anyone with a mushroom allergy should avoid lion’s mane.
Anticoagulant interaction. Some in vitro studies suggest that lion’s mane may have mild antiplatelet activity. While no clinical interactions have been documented, individuals taking blood thinners (warfarin, aspirin, clopidogrel) should exercise caution and consult their physician.
Pregnancy and breastfeeding. There is insufficient safety data for use during pregnancy or lactation. Avoidance is the prudent default.
Overall, lion’s mane is well-tolerated by the vast majority of users and carries a low risk profile. It does not cause the jitteriness or sleep disruption associated with stimulant-based nootropics, and it does not interact with common medications in any well-documented way.
How Does Lion’s Mane Compare to Better-Studied Nootropics?
Context matters. Lion’s mane is often discussed alongside other cognitive supplements, and it is worth being honest about where it stands in that lineup.
Omega-3 (DHA/EPA) has the deepest evidence base of any brain supplement, supported by large-scale RCTs, meta-analyses, and structural neuroimaging data demonstrating that DHA is literally incorporated into neuronal membranes. Lion’s mane is not in the same evidentiary category.
Creatine monohydrate has been studied in dozens of cognitive trials with consistent benefits for short-term memory and reasoning under stress or in creatine-depleted populations. The meta-analytic evidence (Avgerinos et al., 2018) is stronger than what exists for lion’s mane.
Citicoline has Cochrane-reviewed evidence for cognitive benefits in aging populations. Again, the evidence base is deeper and more mature than lion’s mane.
Bacopa monnieri has a comparable evidence profile to lion’s mane – small but positive RCTs, a plausible mechanism, and a need for longer supplementation periods. Both are in the “moderate promise, needs more research” category.
Ginkgo biloba has been decisively shown to be ineffective in large-scale trials. Lion’s mane is in a better position than ginkgo because its major trials have been positive, but it has not yet faced the kind of rigorous, large-sample scrutiny that revealed ginkgo’s limitations.
The fair conclusion: lion’s mane is a second-tier supplement with genuine biological plausibility and encouraging preliminary data, but it should not be the first supplement someone reaches for when building an evidence-based cognitive health stack. Start with the better-studied compounds; consider lion’s mane as an addition if the foundations are already in place.
Practical Takeaway
Lion’s mane is genuinely interesting, not just hype. The NGF-stimulating mechanism is well-supported in preclinical research, and the available human trials are positive. But the clinical evidence is still preliminary – small sample sizes, limited independent replication, and no large-scale confirmatory trials.
Supplement quality varies wildly. Many commercial lion’s mane products are mycelium-on-grain preparations that contain more starch than fungal bioactives. Choose a dual-extract product made from fruiting body (or verified erinacine-rich mycelium from submerged culture), standardized for at least 25 percent beta-glucans.
Use 1,000–3,000 mg/day of a quality extract. Take it with food, split across one or two doses. Allow 8–12 weeks for potential effects to emerge.
Do not use lion’s mane as your primary cognitive supplement. If you are new to evidence-based supplementation, omega-3/DHA, creatine monohydrate, and citicoline all have stronger evidence bases. Lion’s mane makes more sense as a complementary addition, not a starting point.
Be skeptical of dramatic claims. Lion’s mane does not “regrow your brain” or “cure brain fog.” It may modestly support cognitive function in aging adults, particularly those with mild impairment. Set expectations accordingly.
Consult your physician if you take blood thinners, immunosuppressants, or any medication that could interact with a supplement affecting platelet function or immune modulation.
Frequently Asked Questions
Can lion’s mane actually stimulate nerve growth factor in the human brain?
In cell culture and animal studies, yes – the evidence for NGF stimulation by hericenones and erinacines is robust. Whether orally consumed lion’s mane supplements produce clinically meaningful increases in NGF in the living human brain has not been directly measured. The cognitive improvements seen in human trials are consistent with an NGF-mediated mechanism, but circulating NGF levels were not assessed in those studies. This remains a key gap in the research.
How long does it take for lion’s mane to work?
The clinical trials that showed positive results used supplementation periods of 8 to 16 weeks. Do not expect acute effects from a single dose or even a few days of use. Lion’s mane works – if it works – through gradual biological processes like NGF upregulation, neurite outgrowth, and myelin support. These are slow processes. If you notice a dramatic cognitive effect within hours, it is almost certainly a placebo response.
Is lion’s mane safe to take every day long-term?
Based on the available evidence, daily use at standard doses (up to 3 g/day) appears safe. The longest published clinical trial ran for 49 weeks (Li et al., 2020) without serious adverse events. Traditional use in East Asia spans centuries. However, there are no multi-year safety studies in Western populations, so some degree of uncertainty remains for very long-term use.
Should I choose fruiting body or mycelium supplements?
For most consumers, a fruiting body extract or a dual-extract product combining fruiting body and mycelium is the best choice. Fruiting body products have higher beta-glucan and hericenone content. If you specifically want erinacines (which are primarily in the mycelium), look for products made from liquid-cultured mycelium with verified erinacine content – not mycelium grown on grain, which is likely to be starch-heavy.
Can I stack lion’s mane with other nootropics?
Lion’s mane works through a distinct mechanism (NGF stimulation) that does not overlap with the mechanisms of omega-3, creatine, citicoline, or caffeine. There are no known adverse interactions between lion’s mane and these commonly used supplements. However, the principle of parsimony applies: do not add compounds to your stack without a specific rationale, and give each new addition enough time (8-12 weeks) to evaluate its effects before adding another.
Does cooking lion’s mane destroy the active compounds?
Cooking fresh lion’s mane at typical culinary temperatures likely reduces some heat-sensitive compounds but does not eliminate all bioactives. Beta-glucans, in particular, are relatively heat-stable. However, the concentration of hericenones and erinacines in a fresh culinary serving is much lower than in a concentrated extract. If cognitive support is your goal, supplementation with a standardized extract is more reliable than eating the mushroom as food – though there is certainly no harm in enjoying it at the dinner table as well.
Sources
Kawagishi, H., Ando, M., Sakamoto, H., Yoshida, S., Ojima, F., Ishiguro, Y., … & Hongo, I. (1991). Hericenones C, D and E, stimulators of nerve growth factor (NGF)-synthesis, from the mushroom Hericium erinaceum. Tetrahedron Letters, 32(35), 4561–4564.
Kawagishi, H., Shimada, A., Shirai, R., Okamoto, K., Ojima, F., Sakamoto, H., … & Furukawa, S. (1994). Erinacines A, B, and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Letters, 35(10), 1569–1572.
Kawagishi, H., Shimada, A., Hosokawa, S., Mori, H., Sakamoto, H., Ishiguro, Y., … & Furukawa, S. (1996). Erinacines E, F, and G, stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Letters, 37(41), 7399–7402.
Mori, K., Obara, Y., Hirota, M., Azumi, Y., Kinugasa, S., Inatomi, S., & Nakahata, N. (2008). Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biological and Pharmaceutical Bulletin, 31(9), 1727–1732.
Mori, K., Inatomi, S., Ouchi, K., Azumi, Y., & Tuchida, T. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: A double-blind placebo-controlled clinical trial. Phytotherapy Research, 23(3), 367–372.
Saitsu, Y., Nishide, A., Kikushima, K., Shimizu, K., & Ohnuki, K. (2019). Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomedical Research, 40(4), 125–131.
Li, I. C., Chang, H. H., Lin, C. H., Chen, W. P., Lu, T. H., Lee, L. Y., … & Chen, C. C. (2020). Prevention of early Alzheimer’s disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study. Frontiers in Aging Neuroscience, 12, 155.
Brandalise, F., Cesaroni, V., Vilber, A., Bhatt, M., Bhatt, S., & Bhatt, J. (2017). Dietary supplementation of Hericium erinaceus increases mossy fiber-CA3 hippocampal neurotransmission and recognition memory in wild-type mice. Evidence-Based Complementary and Alternative Medicine, 2017, 3864340.
Kolotushkina, E. V., Moldavan, M. G., Voronin, K. Y., & Skibo, G. G. (2003). The influence of Hericium erinaceus extract on myelination process in vitro. Fiziolohichnyi Zhurnal, 49(1), 38–45.
Zhang, C. C., Cao, C. Y., Kubo, M., Harada, K., Yan, X. T., Fukuyama, Y., & Gao, J. M. (2017). Chemical constituents from Hericium erinaceus promote neuronal survival and potentiate neurite outgrowth via the TrkA/Erk1/2 pathway. International Journal of Molecular Sciences, 18(8), 1659.
Friedman, M. (2015). Chemistry, nutrition, and health-promoting properties of Hericium erinaceus (lion’s mane) mushroom fruiting bodies and mycelia and their bioactive compounds. Journal of Agricultural and Food Chemistry, 63(32), 7108–7123.
Chong, P. S., Fung, M. L., Wong, K. H., & Lim, L. W. (2020). Therapeutic potential of Hericium erinaceus for depressive disorder. International Journal of Molecular Sciences, 21(1), 163.